Viking Therapeutics' Obesity Drug Shows Strong Results, Shares Soar.
TL;DR Summary
Viking Therapeutics' experimental obesity drug, VK2735, was safe and helped reduce weight by up to 6% in an early-stage study of about 88 patients. The drugmaker plans to begin a mid-stage trial for the drug in mid-2023, entering the race to develop an obesity treatment market expected to hit $50 billion in sales by 2030. Shares of Viking Therapeutics rose nearly 50% in pre-market trading.
- UPDATE 2-Viking Therapeutics obesity drug shows promise in early-stage study, shares soar Yahoo Finance
- Why Viking Therapeutics Stock Is Soaring Tuesday - Viking Therapeutics (NASDAQ:VKTX) Benzinga
- Viking Therapeutics weight loss drug posts strong results STAT
- VKTX Stock Catapults Higher On Its Obesity Treatment Scorcher | Investor's Business Daily Investor's Business Daily
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
79%
306 → 65 words
Want the full story? Read the original article
Read on Yahoo Finance